Dallah Healthcare Valuation
Is 4004 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4004 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4004 (SAR116.2) is trading below our estimate of fair value (SAR154.87)
Significantly Below Fair Value: 4004 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4004?
Key metric: As 4004 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 4004's PE Ratio? | |
|---|---|
| PE Ratio | 23.2x |
| Earnings | ر.س507.46m |
| Market Cap | ر.س11.82b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.6x |
| Enterprise Value/EBITDA | 21.1x |
| PEG Ratio | 1.7x |
Price to Earnings Ratio vs Peers
How does 4004's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 23.7x | ||
4017 Dr. Soliman Abdel Kader Fakeeh Hospital | 34.3x | 15.20% | ر.س10.1b |
4002 Mouwasat Medical Services | 21.9x | 11.89% | ر.س14.8b |
4005 National Medical Care | 24.7x | 11.59% | ر.س7.5b |
4009 Middle East Healthcare | 14.1x | 5.81% | ر.س5.6b |
4004 Dallah Healthcare | 23.2x | 13.45% | ر.س11.8b |
Price-To-Earnings vs Peers: 4004 is good value based on its Price-To-Earnings Ratio (23.2x) compared to the peer average (23.7x).
Price to Earnings Ratio vs Industry
How does 4004's PE Ratio compare vs other companies in the SA Healthcare Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 4004 is good value based on its Price-To-Earnings Ratio (23.2x) compared to the SA Healthcare industry average (24.5x).
Price to Earnings Ratio vs Fair Ratio
What is 4004's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 23.2x |
| Fair PE Ratio | 25.7x |
Price-To-Earnings vs Fair Ratio: 4004 is good value based on its Price-To-Earnings Ratio (23.2x) compared to the estimated Fair Price-To-Earnings Ratio (25.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ر.س116.20 | ر.س147.66 +27.07% | 19.65% | ر.س183.00 | ر.س92.20 | n/a | 10 |
| May ’26 | ر.س120.60 | ر.س147.37 +22.20% | 20.07% | ر.س183.00 | ر.س89.30 | n/a | 10 |
| Apr ’26 | ر.س126.60 | ر.س159.08 +25.66% | 13.78% | ر.س183.00 | ر.س113.00 | n/a | 10 |
| Mar ’26 | ر.س144.20 | ر.س164.58 +14.13% | 13.46% | ر.س192.00 | ر.س117.00 | n/a | 10 |
| Feb ’26 | ر.س159.20 | ر.س164.78 +3.51% | 13.50% | ر.س192.00 | ر.س117.00 | n/a | 10 |
| Jan ’26 | ر.س151.00 | ر.س164.78 +9.13% | 13.50% | ر.س192.00 | ر.س117.00 | n/a | 10 |
| Dec ’25 | ر.س150.80 | ر.س163.58 +8.47% | 12.88% | ر.س192.00 | ر.س117.00 | n/a | 10 |
| Nov ’25 | ر.س159.60 | ر.س163.38 +2.37% | 13.17% | ر.س192.00 | ر.س115.00 | n/a | 10 |
| Oct ’25 | ر.س160.00 | ر.س163.78 +2.36% | 13.31% | ر.س192.00 | ر.س115.00 | n/a | 10 |
| Sep ’25 | ر.س160.00 | ر.س162.87 +1.79% | 14.00% | ر.س192.00 | ر.س115.00 | n/a | 9 |
| Aug ’25 | ر.س161.80 | ر.س156.20 -3.46% | 13.99% | ر.س183.00 | ر.س109.00 | n/a | 9 |
| Jul ’25 | ر.س154.20 | ر.س155.88 +1.09% | 12.96% | ر.س183.00 | ر.س109.00 | n/a | 10 |
| Jun ’25 | ر.س165.00 | ر.س155.18 -5.95% | 12.91% | ر.س183.00 | ر.س109.00 | n/a | 10 |
| May ’25 | ر.س162.00 | ر.س154.38 -4.70% | 13.23% | ر.س183.00 | ر.س106.00 | ر.س120.60 | 10 |
| Apr ’25 | ر.س171.40 | ر.س150.09 -12.43% | 12.52% | ر.س174.00 | ر.س106.00 | ر.س126.60 | 9 |
| Mar ’25 | ر.س187.60 | ر.س147.26 -21.51% | 16.02% | ر.س165.00 | ر.س85.80 | ر.س144.20 | 9 |
| Feb ’25 | ر.س165.20 | ر.س142.37 -13.82% | 16.75% | ر.س165.00 | ر.س85.80 | ر.س159.20 | 9 |
| Jan ’25 | ر.س170.40 | ر.س142.37 -16.45% | 16.75% | ر.س165.00 | ر.س85.80 | ر.س151.00 | 9 |
| Dec ’24 | ر.س166.00 | ر.س136.70 -17.65% | 16.90% | ر.س165.00 | ر.س85.80 | ر.س150.80 | 9 |
| Nov ’24 | ر.س145.80 | ر.س134.09 -8.03% | 19.58% | ر.س170.50 | ر.س74.30 | ر.س159.60 | 9 |
| Oct ’24 | ر.س142.00 | ر.س133.48 -6.00% | 20.82% | ر.س170.50 | ر.س74.30 | ر.س160.00 | 8 |
| Sep ’24 | ر.س140.00 | ر.س135.98 -2.88% | 20.12% | ر.س170.50 | ر.س74.30 | ر.س160.00 | 8 |
| Aug ’24 | ر.س173.80 | ر.س132.46 -23.78% | 23.67% | ر.س170.50 | ر.س76.20 | ر.س161.80 | 8 |
| Jul ’24 | n/a | ر.س134.21 0% | 25.00% | ر.س181.00 | ر.س76.20 | ر.س154.20 | 8 |
| Jun ’24 | ر.س163.40 | ر.س128.09 -21.61% | 25.78% | ر.س181.00 | ر.س76.20 | ر.س165.00 | 8 |
| May ’24 | ر.س170.00 | ر.س119.98 -29.43% | 26.41% | ر.س176.00 | ر.س66.80 | ر.س162.00 | 7 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 04:40 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dallah Healthcare Company is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ibrahim Elaiwat | Aljazira Capital Company |
| Jassim Al-Jubran | Aljazira Capital Company |
| Rim Ben Salah Gharbi | AlphaMena |